The authors reply

Kidney Int. 2021 Apr;99(4):1026. doi: 10.1016/j.kint.2021.01.009.

Authors

Hirofumi Hamano¹, Masayuki Chuma², Kenshi Takechi², Yasumasa Ikeda³

Affiliations

¹ Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
² Clinical Trial Center for Developmental Therapeutics, Tokushima University Hospital, Tokushima, Japan.
³ Department of Pharmacology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. Electronic address: yasuike@tokushima-u.ac.jp.

PMID: 33745535
DOI: 10.1016/j.kint.2021.01.009

No abstract available

Publication types

Letter
Comment

MeSH terms

Cisplatin
Diphenhydramine
Drug-Related Side Effects and Adverse Reactions*
Humans
Kidney
Renal Insufficiency*

Substances

Diphenhydramine
Cisplatin